A 5-year multicenter prospective cohort study on the long-term visual prognosis and predictive factors for visual outcome in Japanese patients with age-related macular degeneration: the AMD2000 study

AMD2000 Study Group

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: In this study (AMD2000), we aimed to determine the visual prognosis of Japanese patients with age-related macular degeneration (AMD). Methods: This was a multicenter prospective observational cohort study. In total, 460 patients with AMD were recruited from April 2006 to March 2009 from 18 clinical trial sites in Japan. They were followed up for 5 years, as they continued to receive medical treatment. Results: Of the 409 study eyes followed up for at least 1 year, 243 eyes (59.4%) were treated with photodynamic therapy (PDT) using verteporfin, and 58 eyes (14.2%) were treated with intravitreal injections of antivascular endothelial growth factor agents as the initial treatment. The mean best-corrected visual acuities (BCVA) for typical AMD (tAMD; 0.688 ± 0.498) and polypoidal choroidal vasculopathy (PCV; 0.451 ± 0.395) were significantly less at 2 years (tAMD, 0.779 ± 0.632, P < 0.05; PCV, 0.534 ± 0.618, P < 0.05) and at 5 years (AMD, 0.873 ± 0.718, P < 0.05; PCV, 0.635 ± 0.668, P < 0.05) than at baseline. In eyes with tAMD, absence of blocked fluorescence was associated with 5-year maintenance of the baseline BCVA. Regarding PCV, the presence of polypoidal lesions and cystoid macular edema as well as the lesion size was associated with 5-year maintenance of the baseline BCVA. In some patients, the diagnosis changed: of the 192 eyes initially diagnosed with typical AMD, 19 were newly diagnosed with PCV during follow-up. Conclusion: Maintaining the baseline BCVA over the long term is difficult in Japanese eyes with wet AMD.

Original languageEnglish
Pages (from-to)137-143
Number of pages7
JournalJapanese Journal of Ophthalmology
Volume62
Issue number2
DOIs
Publication statusPublished - Mar 1 2018

Fingerprint

Macular Degeneration
Cohort Studies
Prospective Studies
Visual Acuity
Maintenance
Endothelial Growth Factors
Intravitreal Injections
Macular Edema
Photochemotherapy
Observational Studies
Japan
Fluorescence
Clinical Trials
Therapeutics

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

@article{271388eb92c44196ac3c800f8f0a4cbe,
title = "A 5-year multicenter prospective cohort study on the long-term visual prognosis and predictive factors for visual outcome in Japanese patients with age-related macular degeneration: the AMD2000 study",
abstract = "Purpose: In this study (AMD2000), we aimed to determine the visual prognosis of Japanese patients with age-related macular degeneration (AMD). Methods: This was a multicenter prospective observational cohort study. In total, 460 patients with AMD were recruited from April 2006 to March 2009 from 18 clinical trial sites in Japan. They were followed up for 5 years, as they continued to receive medical treatment. Results: Of the 409 study eyes followed up for at least 1 year, 243 eyes (59.4{\%}) were treated with photodynamic therapy (PDT) using verteporfin, and 58 eyes (14.2{\%}) were treated with intravitreal injections of antivascular endothelial growth factor agents as the initial treatment. The mean best-corrected visual acuities (BCVA) for typical AMD (tAMD; 0.688 ± 0.498) and polypoidal choroidal vasculopathy (PCV; 0.451 ± 0.395) were significantly less at 2 years (tAMD, 0.779 ± 0.632, P < 0.05; PCV, 0.534 ± 0.618, P < 0.05) and at 5 years (AMD, 0.873 ± 0.718, P < 0.05; PCV, 0.635 ± 0.668, P < 0.05) than at baseline. In eyes with tAMD, absence of blocked fluorescence was associated with 5-year maintenance of the baseline BCVA. Regarding PCV, the presence of polypoidal lesions and cystoid macular edema as well as the lesion size was associated with 5-year maintenance of the baseline BCVA. In some patients, the diagnosis changed: of the 192 eyes initially diagnosed with typical AMD, 19 were newly diagnosed with PCV during follow-up. Conclusion: Maintaining the baseline BCVA over the long term is difficult in Japanese eyes with wet AMD.",
author = "{AMD2000 Study Group} and Yumiko Akagi-Kurashige and Akitaka Tsujikawa and Mitsuko Yuzawa and Tatsuro Ishibashi and Tatsuro Ishibashi and Eiji Nakatani and Satoshi Teramukai and Masanori Fukushima and Nagahisa Yoshimura and Muneyasu Takeda and Hiroko Imaizumi and Utako Okushiba and Mitsuru Nakazawa and Yukihiko Suzuki and Hidetoshi Yamashita and Daijiro Tsuchiya and Shoji Kishi and Ryo Mukai and Maki Takahashi and Taku Sato and Hidetaka Matsumoto and Masahiro Miura and Ryuzaburo Mori and Yasuhiro Tamaki and Ryo Obata and Yasuo Yanagi and Takuya Iwasaki and Yasuyuki Yamauchi and Kazuaki Kadonosono and Maiko Inoue and Misa Suzuki and Akira Obana and Masayuki Horiguchi and Atsuhiro Tanikawa and Kenji Yamashiro and Atsushi Otani and Hiroshi Tamura and Ayako Takahashi and Akio Oishi and Fumi Gomi and Miki Sawa and Tsunehiko Ikeda and Masahiro Minami and Kanji Takahashi and Kenichiro Sho and Shigeru Honda and Taiji Sakamoto and Akiko Okubo",
year = "2018",
month = "3",
day = "1",
doi = "10.1007/s10384-017-0554-5",
language = "English",
volume = "62",
pages = "137--143",
journal = "Japanese Journal of Ophthalmology",
issn = "0021-5155",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - A 5-year multicenter prospective cohort study on the long-term visual prognosis and predictive factors for visual outcome in Japanese patients with age-related macular degeneration

T2 - the AMD2000 study

AU - AMD2000 Study Group

AU - Akagi-Kurashige, Yumiko

AU - Tsujikawa, Akitaka

AU - Yuzawa, Mitsuko

AU - Ishibashi, Tatsuro

AU - Ishibashi, Tatsuro

AU - Nakatani, Eiji

AU - Teramukai, Satoshi

AU - Fukushima, Masanori

AU - Yoshimura, Nagahisa

AU - Takeda, Muneyasu

AU - Imaizumi, Hiroko

AU - Okushiba, Utako

AU - Nakazawa, Mitsuru

AU - Suzuki, Yukihiko

AU - Yamashita, Hidetoshi

AU - Tsuchiya, Daijiro

AU - Kishi, Shoji

AU - Mukai, Ryo

AU - Takahashi, Maki

AU - Sato, Taku

AU - Matsumoto, Hidetaka

AU - Miura, Masahiro

AU - Mori, Ryuzaburo

AU - Tamaki, Yasuhiro

AU - Obata, Ryo

AU - Yanagi, Yasuo

AU - Iwasaki, Takuya

AU - Yamauchi, Yasuyuki

AU - Kadonosono, Kazuaki

AU - Inoue, Maiko

AU - Suzuki, Misa

AU - Obana, Akira

AU - Horiguchi, Masayuki

AU - Tanikawa, Atsuhiro

AU - Yamashiro, Kenji

AU - Otani, Atsushi

AU - Tamura, Hiroshi

AU - Takahashi, Ayako

AU - Oishi, Akio

AU - Gomi, Fumi

AU - Sawa, Miki

AU - Ikeda, Tsunehiko

AU - Minami, Masahiro

AU - Takahashi, Kanji

AU - Sho, Kenichiro

AU - Honda, Shigeru

AU - Sakamoto, Taiji

AU - Okubo, Akiko

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Purpose: In this study (AMD2000), we aimed to determine the visual prognosis of Japanese patients with age-related macular degeneration (AMD). Methods: This was a multicenter prospective observational cohort study. In total, 460 patients with AMD were recruited from April 2006 to March 2009 from 18 clinical trial sites in Japan. They were followed up for 5 years, as they continued to receive medical treatment. Results: Of the 409 study eyes followed up for at least 1 year, 243 eyes (59.4%) were treated with photodynamic therapy (PDT) using verteporfin, and 58 eyes (14.2%) were treated with intravitreal injections of antivascular endothelial growth factor agents as the initial treatment. The mean best-corrected visual acuities (BCVA) for typical AMD (tAMD; 0.688 ± 0.498) and polypoidal choroidal vasculopathy (PCV; 0.451 ± 0.395) were significantly less at 2 years (tAMD, 0.779 ± 0.632, P < 0.05; PCV, 0.534 ± 0.618, P < 0.05) and at 5 years (AMD, 0.873 ± 0.718, P < 0.05; PCV, 0.635 ± 0.668, P < 0.05) than at baseline. In eyes with tAMD, absence of blocked fluorescence was associated with 5-year maintenance of the baseline BCVA. Regarding PCV, the presence of polypoidal lesions and cystoid macular edema as well as the lesion size was associated with 5-year maintenance of the baseline BCVA. In some patients, the diagnosis changed: of the 192 eyes initially diagnosed with typical AMD, 19 were newly diagnosed with PCV during follow-up. Conclusion: Maintaining the baseline BCVA over the long term is difficult in Japanese eyes with wet AMD.

AB - Purpose: In this study (AMD2000), we aimed to determine the visual prognosis of Japanese patients with age-related macular degeneration (AMD). Methods: This was a multicenter prospective observational cohort study. In total, 460 patients with AMD were recruited from April 2006 to March 2009 from 18 clinical trial sites in Japan. They were followed up for 5 years, as they continued to receive medical treatment. Results: Of the 409 study eyes followed up for at least 1 year, 243 eyes (59.4%) were treated with photodynamic therapy (PDT) using verteporfin, and 58 eyes (14.2%) were treated with intravitreal injections of antivascular endothelial growth factor agents as the initial treatment. The mean best-corrected visual acuities (BCVA) for typical AMD (tAMD; 0.688 ± 0.498) and polypoidal choroidal vasculopathy (PCV; 0.451 ± 0.395) were significantly less at 2 years (tAMD, 0.779 ± 0.632, P < 0.05; PCV, 0.534 ± 0.618, P < 0.05) and at 5 years (AMD, 0.873 ± 0.718, P < 0.05; PCV, 0.635 ± 0.668, P < 0.05) than at baseline. In eyes with tAMD, absence of blocked fluorescence was associated with 5-year maintenance of the baseline BCVA. Regarding PCV, the presence of polypoidal lesions and cystoid macular edema as well as the lesion size was associated with 5-year maintenance of the baseline BCVA. In some patients, the diagnosis changed: of the 192 eyes initially diagnosed with typical AMD, 19 were newly diagnosed with PCV during follow-up. Conclusion: Maintaining the baseline BCVA over the long term is difficult in Japanese eyes with wet AMD.

UR - http://www.scopus.com/inward/record.url?scp=85037635290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037635290&partnerID=8YFLogxK

U2 - 10.1007/s10384-017-0554-5

DO - 10.1007/s10384-017-0554-5

M3 - Article

C2 - 29224056

AN - SCOPUS:85037635290

VL - 62

SP - 137

EP - 143

JO - Japanese Journal of Ophthalmology

JF - Japanese Journal of Ophthalmology

SN - 0021-5155

IS - 2

ER -